Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Citizen Petitions: FDA Will Speed Reviews Via Centralization, Not Decoupling

Executive Summary

FDA is taking several administrative steps toward streamlining its review of citizen petitions, including designating staff to concentrate on the submissions

You may also be interested in...



ANDA Review Improvements Continue As FDA Eyes Generic User Fee Resources

FDA's review backlog for ANDAs requires a "significant" improvement in resources, Office of Generic Drugs Director Gary Buehler said

ANDA Review Improvements Continue As FDA Eyes Generic User Fee Resources

FDA's review backlog for ANDAs requires a "significant" improvement in resources, Office of Generic Drugs Director Gary Buehler said

FDA Will Refer Potentially Anti-Competitive Citizen Petitions To FTC

Questionable citizen petitions will be referred to the Federal Trade Commission, FDA says in a report made to House and Senate appropriations committees

Related Content

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel